These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
173 related items for PubMed ID: 19333142
1. Rosiglitazone reduces the inflammatory response in a model of vascular injury in rats. Rinaldi B, Pieri L, Donniacuo M, Cappetta D, Capuano A, Domenici L, Carnuccio R, Romagnoli P, Filippelli A, Rossi F. Shock; 2009 Dec; 32(6):638-44. PubMed ID: 19333142 [Abstract] [Full Text] [Related]
2. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats. Sánchez-Hidalgo M, Martín AR, Villegas I, de la Lastra CA. Eur J Pharmacol; 2007 May 21; 562(3):247-58. PubMed ID: 17343846 [Abstract] [Full Text] [Related]
3. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia. Liu D, Zeng BX, Zhang SH, Yao SL. Inflamm Res; 2005 Nov 21; 54(11):464-70. PubMed ID: 16307220 [Abstract] [Full Text] [Related]
4. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, Danni O, Thiemermann C, Fantozzi R. Eur J Pharmacol; 2006 Jan 13; 530(1-2):70-80. PubMed ID: 16386242 [Abstract] [Full Text] [Related]
6. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Sánchez-Hidalgo M, Martín AR, Villegas I, Alarcón De La Lastra C. Biochem Pharmacol; 2005 Jun 15; 69(12):1733-44. PubMed ID: 15876425 [Abstract] [Full Text] [Related]
11. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X. Metabolism; 2007 Oct 15; 56(10):1396-401. PubMed ID: 17884451 [Abstract] [Full Text] [Related]
12. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism. Moulin D, Bianchi A, Boyault S, Sebillaud S, Koufany M, Francois M, Netter P, Jouzeau JY, Terlain B. Arthritis Rheum; 2005 Mar 15; 52(3):759-69. PubMed ID: 15751073 [Abstract] [Full Text] [Related]
14. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Abdelrahman M, Sivarajah A, Thiemermann C. Cardiovasc Res; 2005 Mar 01; 65(4):772-81. PubMed ID: 15721857 [Abstract] [Full Text] [Related]
15. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH, Chen J. J Neurochem; 2006 Apr 01; 97(2):435-48. PubMed ID: 16539667 [Abstract] [Full Text] [Related]
16. Rosiglitazone regulates c-reactive protein-induced inflammatory responses via glucocorticoid receptor-mediated inhibition of p38 mitogen-activated protein kinase-toll-like receptor 4 signal pathway in vascular smooth muscle cells. Liu N, Liu JT, Ji YY, Lu PP. J Cardiovasc Pharmacol; 2011 Mar 01; 57(3):348-56. PubMed ID: 21383592 [Abstract] [Full Text] [Related]